Cargando…
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
BACKGROUND: We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults. METHODS: HER-MES was a 24-week, randomised, double-blind, double-dummy, controlled trial conducted in 82...
Autores principales: | Reuter, Uwe, Ehrlich, Marc, Gendolla, Astrid, Heinze, Axel, Klatt, Jan, Wen, Shihua, Hours-Zesiger, Peggy, Nickisch, Jacqueline, Sieder, Christian, Hentschke, Christian, Maier-Peuschel, Monika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793299/ https://www.ncbi.nlm.nih.gov/pubmed/34743579 http://dx.doi.org/10.1177/03331024211053571 |
Ejemplares similares
-
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study
por: Ehrlich, Marc, et al.
Publicado: (2022) -
Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study
por: Lanteri-Minet, Michel, et al.
Publicado: (2021) -
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study
por: Goadsby, Peter J., et al.
Publicado: (2021) -
Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020) -
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)